Welcome to The Visible Embryo
The Visible Embryo Birth Spiral Navigation
Fetal Timeline--- -Maternal Timeline-----News-----Prescription Drugs in Pregnancy---- Pregnancy Calculator----Female Reproductive System

WHO International Clinical Trials Registry Platform

The World Health Organization (WHO) has a Web site to help researchers, doctors and patients obtain information on clinical trials.

Now you can search all such registers to identify clinical trial research around the world!




Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System


Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.

Content protected under a Creative Commons License.
No dirivative works may be made or used for commercial purposes.


Pregnancy Timeline by SemestersDevelopmental TimelineFertilizationFirst TrimesterSecond TrimesterThird TrimesterFirst Thin Layer of Skin AppearsEnd of Embryonic PeriodEnd of Embryonic PeriodFemale Reproductive SystemBeginning Cerebral HemispheresA Four Chambered HeartFirst Detectable Brain WavesThe Appearance of SomitesBasic Brain Structure in PlaceHeartbeat can be detectedHeartbeat can be detectedFinger and toe prints appearFinger and toe prints appearFetal sexual organs visibleBrown fat surrounds lymphatic systemBone marrow starts making blood cellsBone marrow starts making blood cellsInner Ear Bones HardenSensory brain waves begin to activateSensory brain waves begin to activateFetal liver is producing blood cellsBrain convolutions beginBrain convolutions beginImmune system beginningWhite fat begins to be madeHead may position into pelvisWhite fat begins to be madePeriod of rapid brain growthFull TermHead may position into pelvisImmune system beginningLungs begin to produce surfactant
CLICK ON weeks 0 - 40 and follow along every 2 weeks of fetal development


Slowing the progression of muscular dystrophy

Slowing a fatal form of muscular dystrophy relies on the REV-ERB receptor...

Published in the Nature journal Scientific Reports, Saint Louis University (SLU) researchers report a new drug reduces fibrosis (scarring) and prevents loss of muscle function in an animal model of Duchenne muscular dystrophy (DMD).

DMD is a fatal form of a muscle wasting disorder affecting one in every 5,000 to 10,000 boys. It is caused by mutations on the X chromosome in the gene encoding dystrophin protein found in muscle fibers. Dystrophin is a structural protein that protects the sarcolemma membrane surrounding muscles from stresses produced in muscle contractions. However, over the last 10 years more and more evidence reveals the loss of dystrophin causes dysfunction in multiple muscle pathways, all contributing to DMD.

DMD patients go through continuous cycles of muscle destruction and regeneration which promotes inflammed muscle tissue, scarring and eventual loss of function. With treatment, men with DMD live on average about 25 years, needing a wheelchair by age 12, and mechanical ventilation to help their breathing.

Working together, Thomas Burris and Colin Flaveny are hoping to develop synthetic compounds that stimulate nuclear receptors in muscle cells to rescue the affects of DMD. Nuclear hormone receptors are proteins that bind to another target protein to act as on-off switches controlling its function. In their joint research, Burris and Flaveny found a nuclear receptor known to regulate cholesterol.

Cholesterol is one of the most important substances in our body as it helps stabilize the cell membrane. Two types of lipoproteins carry cholesterol to and from cells. One is low-density lipoprotein, or LDL. Colin Flaveny PhD, an assistant professor of pharmacology and physiology at Saint Louis University (SLU), previously studied the nuclear receptor REV-ERB as it regulates our internal clock. Burris as chair of pharmacology and physiology at SLU, works on how a body's natural hormones operate and earlier this year, published new findings showing that REV-ERB is involved in lowering LDL cholesterol.
"Recently, we found that REV-ERB appears to play a unique role in every stage of muscle tissue development."

Colin A. Flaveny PhD, Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.

Together, Flaveny and Burris identified that a decrease in funcion of REV-ERB leads myoblast or muscle cells to differentiate. Conversely, an increase in REV-ERB function affects the metabolic function of skeletal muscle. Knowing that a drug called SR8278 inhibits REV-ERB, Burris and Flaveny explored whether SR8278 could slow the progression of muscular dystrophy in a mouse modelling the disorder. They observed in mice that SR8278 increased lean muscle mass and function while decreasing muscle scarring and protein loss.
"These results suggest that REV-ERB is a potent target for treatment of DMD. This is an encouraging finding as we search for better treatments for this debilitating illness."

Thomas P. Burris PhD, Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA

Duchenne muscular dystrophy (DMD) is a debilitating X-linked disorder that is fatal. DMD patients lack the expression of the structural protein dystrophin caused by mutations within the DMD gene. The absence of functional dystrophin protein results in excessive damage from normal muscle use due to the compromised structural integrity of the dystrophin associated glycoprotein complex. As a result, DMD patients exhibit ongoing cycles of muscle destruction and regeneration that promote inflammation, fibrosis, mitochondrial dysfunction, satellite cell (SC) exhaustion and loss of skeletal and cardiac muscle function. The nuclear receptor REV-ERB suppresses myoblast differentiation and recently we have demonstrated that the REV-ERB antagonist, SR8278, stimulates muscle regeneration after acute injury. Therefore, we decided to explore whether the REV-ERB antagonist SR8278 could slow the progression of muscular dystrophy. In mdx mice SR8278 increased lean mass and muscle function, and decreased muscle fibrosis and muscle protein degradation. Interestingly, we also found that SR8278 increased the SC pool through stimulation of Notch and Wnt signaling. These results suggest that REV-ERB is a potent target for the treatment of DMD.

Authors: Ryan D. Welch, Cyrielle Billon, Aurore-Cecile Valfort, Thomas P. Burris & Colin A. Flaveny.

Other researchers on the project include Ryan D. Welch, Cyrielle Billon and Aurore-Cecile Valfort.

Wnt Modulators
After 48 hours of differentiating, cells where exposed to 5uM of SR8278 in a DMSO vehicle with or without the presence of LiCl (10 mM, Sigma Aldrich) or WntC59 (100uM, Bio-Techne) for 48 hours. The media with ligand and/or wnt modulators where replenished every 24 hours. The C2C12 cells were then lysed and their RNA isolated for future qPCR analysis.

The study was supported by a grant from the National Institutes of Health (grant number MH093429).

Return to top of page

Dec 11, 2017   Fetal Timeline   Maternal Timeline   News   News Archive

Muscular Dystrophy discussion with kids.
Image credit: Watch video of this discussion filmed by Cut.com

Phospholid by Wikipedia